Cost-effective analysis of topical chlorhexidine in hematologic patients at risk for oral mucositis

Clinical Oral Investigations
Sharon Elad, Todd Thierer

Abstract

The aim of this study was to explore whether management of mucositis with Chlorhexidine (CHX) mouthwash could be a cost-effective method to decrease the risk of mortality and economic burden in hemato-oncologic or hematopoietic stem cell transplantation (HSCT) patients. A cost-effectiveness analysis model of prophylactic CHX mouthwash use versus no-CHX mouthwash use for the prevention of oral mucositis was developed for patients undergoing cytotoxic therapy or HSCT. The outcome variable was survival. The primary variables were CHX mouthwash use, probability of mucositis, probability of increased hospital stay, and length of hospital stay. Probability and cost data were obtained from the literature. Our analysis selected CHX mouthwash use during anticancer treatment as the preferred strategy for the base-case analysis as compared to no CHX mouthwash (marginal value 0.032). There was a $14,391 cost difference per patient between the two strategies. The results of this study suggest that CHX mouthwash use during anticancer treatment results in an increased survival and decreased cost for the population studied. Using our base-case data, an additional 32 of every 1,000 hemato-oncologic or HSCT patients will survive when employing t...Continue Reading

References

Sep 1, 1985·Oral Surgery, Oral Medicine, and Oral Pathology·W T McGaw, A Belch
Apr 1, 1997·Medical Decision Making : an International Journal of the Society for Medical Decision Making·A S DetskyD A Redelmeier
Apr 1, 1997·Medical Decision Making : an International Journal of the Society for Medical Decision Making·A S DetskyD Naimark
Apr 1, 1997·Medical Decision Making : an International Journal of the Society for Medical Decision Making·G NaglieA S Detsky
Apr 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S T SonisM Horowitz
Apr 2, 2004·Nature Reviews. Cancer·Stephen T Sonis
Dec 17, 2004·The New England Journal of Medicine·Ricardo SpielbergerChristos Emmanouilides
Jun 16, 2006·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Andrei BaraschJoel Epstein
Dec 2, 2006·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Montserrat Vera-LlonchStephen Sonis
Jan 20, 2007·Cancer·Dorothy M KeefeUNKNOWN Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral
Apr 15, 2011·The Cochrane Database of Systematic Reviews·Helen V WorthingtonTasneem Khalid
Jun 29, 2011·Anti-cancer Drugs·Stephen T Sonis
Sep 11, 2013·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Deborah B McGuireUNKNOWN Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (
Mar 13, 2014·Cancer·Rajesh V LallaUNKNOWN Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Societ
Mar 25, 2014·Dental Clinics of North America·Rajesh V LallaDouglas E Peterson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.